These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 23186975

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
    Fakhoury WK, Lereun C, Wright D.
    Pharmacology; 2010; 86(1):44-57. PubMed ID: 20616619
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
    Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M, 1860-LIRA-DPP-4 Study Group.
    Int J Clin Pract; 2011 Apr; 65(4):397-407. PubMed ID: 21355967
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin.
    Violante R, Oliveira JH, Yoon KH, Reed VA, Yu MB, Bachmann OP, Lüdemann J, Chan JY.
    Diabet Med; 2012 Nov; 29(11):e417-24. PubMed ID: 22375612
    [Abstract] [Full Text] [Related]

  • 10. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L, LEAD-6 Study Group.
    Lancet; 2009 Jul 04; 374(9683):39-47. PubMed ID: 19515413
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
    Montilla S, Marchesini G, Sammarco A, Trotta MP, Siviero PD, Tomino C, Melchiorri D, Pani L, AIFA Anti-diabetics Monitoring Group.
    Nutr Metab Cardiovasc Dis; 2014 Dec 04; 24(12):1346-53. PubMed ID: 25300980
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
    Gadde KM, Vetter ML, Iqbal N, Hardy E, Öhman P, DURATION-NEO-2 study investigators.
    Diabetes Obes Metab; 2017 Jul 04; 19(7):979-988. PubMed ID: 28205322
    [Abstract] [Full Text] [Related]

  • 16. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
    Thompson AM, Trujillo JM.
    Ann Pharmacother; 2015 Mar 04; 49(3):351-9. PubMed ID: 25565404
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC, Conner C, Hammer M.
    Clin Ther; 2010 Sep 04; 32(10):1756-67. PubMed ID: 21194600
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes.
    Lee WC, Dekoven M, Bouchard J, Massoudi M, Langer J.
    Diabetes Obes Metab; 2014 Sep 04; 16(9):819-26. PubMed ID: 24581276
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.